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Background. Attention-deﬁcit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by high
rates of co-morbid psychopathology. Randomized controlled trials of multimodal interventions, combining pharmaco-
logical and psychological treatments, have shown a robust treatment effect for ADHD symptoms but outcomes for
co-morbid symptoms have been mixed. This may be accounted for by the type of intervention selected and/or by
methodological problems including lack of follow-up and low power. The current study addressed these limitations
in a parallel-group randomized controlled trial conducted in Iceland.
Method. A total of 95 adult ADHD patients who were already being treated with medication (MED) were randomly
assigned to receive treatment as usual (TAU/MED) or 15 sessions of cognitive–behavioural therapy (CBT/MED) using
the R&R2ADHD intervention which employs both group and individual modalities. Primary measures of ADHD symp-
toms and severity of illness, and secondary measures of anxiety, depression and quality of life were given at baseline, end
of treatment and 3-month follow-up. Primary outcomes were rated by clinicians blind to treatment condition assignment.
Results. CBT/MED showed overall (combined outcome at end of treatment and 3-month follow-up) signiﬁcantly greater
reduction in primary outcomes for clinician-rated and self-rated ADHD symptoms. Treatment effect of primary out-
comes was maintained at follow-up, which suggests robust and lasting ﬁndings. In contrast to the primary outcomes,
the secondary outcomes showed signiﬁcant improvement over time.
Conclusions. The study provides evidence for the effectiveness of R&R2ADHD and demonstrates that there are differ-
ential effects over time for ADHD symptoms versus co-morbid problems, the latter taking longer to show positive effects.
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Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a
common neurodevelopmental disorder characterized
by core symptoms of inattention, hyperactivity and/or
impulsivity and associated with signiﬁcant social, edu-
cational and occupational impairments. Longitudinal
and epidemiological studies have shown ADHD to be
a chronic life-long condition emerging in childhood
(Biederman & Faraone, 2005; Sobanski et al. 2007;
Young & Amarasinghe, 2010; Guldberg-Kjär et al.
2013). Meta-analytic reviews have estimated the preva-
lence of ADHD in adulthood to be 2.5–5% (Simon et al.
2009; Willcutt, 2012). It is a complex disorder character-
ized by high rates of co-morbidity including mood
disorders, anxiety, alcohol and drug abuse, and inter-
personal relationship problems (Pliszka, 1998; Shaw
et al. 2012). Indeed cross-sectional, retrospective and
follow-up studies have indicated that ADHD patients
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are up to 80% more likely to develop other psychiatric
difﬁculties (Sobanski et al. 2007; Barkley et al. 2008).
A large, nationally representative US sample demon-
strated that ADHD had an increased lifetime preva-
lence of all psychiatric disorders, even after adjusting
for sociodemographic characteristics (Bernardi et al.
2012).
In the UK, pharmacological interventions are the
ﬁrst-line recommended treatment of ADHD in adults
(National Institute for Health and Clinical Excellence,
2009; Bolea-Alamañac et al. 2014) andmeta-analytic stud-
ies have reported a medium to large treatment effect
(Mészáros et al. 2009). However, up to 50% of medicated
adults may not fully respond to medication (Wender,
1998; Wilens et al. 2002; Prince, 2006; Safren, 2006). By
contrast, psychological treatments have received less
attention but generally support that medication signiﬁ-
cantly augments the outcome of therapy; a systematic
review examining the effect of treatment modality on
long-term outcomes concluded that the combination of
pharmacological and non-pharmacological treatment
was most consistently associated with improved long-
term outcomes and large effect sizes. Furthermore, the
age of treatment initiation and duration of treatment
did not markedly affect the proportion of improved out-
comes reported (Shaw et al. 2012). Only one study has
been conducted comparing participants randomized to
receive combined cognitive–behavioural therapy (CBT)
and medication (dextroamphetamine) versus CBT and
placebo; this study found ADHD symptom outcomes
using CBT alone were as good as when both medication
andCBT interventionswere combined (Weiss et al. 2012).
These ﬁndings are impressive and have great implica-
tions for treatment with CBT as a stand-alone interven-
tion in this population. However the ﬁndings need to
be replicated.
International guidelines recommend a multimodal
treatment approach comprising both pharmacological
and psychological interventions (Seixas et al. 2012).
The common clinical reality, however, is a reliance on
medication as ﬁrst line. This is due to the limited
evidence base currently available for psychological
intervention for treating adults with ADHD. More re-
search is needed in this area and this study makes an
important contribution to the ﬁeld. When choosing
psychological interventions, the selection of group-
delivered treatment is preferable as it is resource
and cost effective (National Institute for Health and
Clinical Excellence, 2009). Randomized controlled
trials (RCTs) that evaluate the combination of these
treatments (versusmedication alone) have reported me-
dium to large treatment effects for both self-rated and
clinician-rated improvements in ADHD symptoms
(Stevenson et al. 2002; Safren et al. 2005, 2010; Safren,
2006). Furthermore, some treatment effects appear to
be robust, with two studies reporting sustained effects
1 year later (Stevenson et al. 2002; Safren et al. 2010).
There have only been three RCTs involving a group
psychological intervention that have evaluated co-
morbid psychopathology at outcome (i.e. anxiety and
depression). These have reported mixed ﬁndings; in
contrast to the ﬁndings of Emilsson et al. (2011), two
studies reported no signiﬁcant improvement in symp-
toms (Solanto et al. 2010; Hirvikoski et al. 2011). The
weakness with the latter two studies is that there
were no follow-up data, which means that any possible
reduction in co-morbid symptoms after the end of
treatment was not assessed. Emilsson et al. (2011) com-
pared medicated patients randomly assigned to either
receive medication (MED) and CBT (CBT/MED) or
treatment as usual (TAU/MED) and reported large
treatment effects at 3-month follow-up for self-rated at-
tention, hyperactivity/impulsivity, anxiety, depression,
emotional control, antisocial behaviour and social
functioning and clinician ratings of illness severity
and ADHD core symptoms. However, there was no
signiﬁcant treatment effect for anxiety and depression
at the end of treatment, which is consistent with the
Hirvikoski et al. (2011) and Solanto et al. (2010) studies,
and suggests that co-morbid problems may take longer
to show positive effect than the core ADHD symptoms.
This ﬁnding requires further investigation.
However, the Emilsson et al. (2011) community study
only involved 54 participants, 27 in each group, and
there was a substantial amount of missing data at the
end of treatment and at 3-month follow-up for both the
CBT/MED and TAU/MED groups. The presence of miss-
ing data may potentially lead to a biased estimate of the
treatment effect, which was not appropriately dealt
with in the previous study due to the limitations of the
statistical approach taken. For example, there is evidence
that age and antisocial personality (ASP) traits are signiﬁ-
cant predictors of failure to attend follow-up appoint-
ments (Gudjonsson et al. 2004). A recommended way
(White et al. 2011) to reduce possible bias is to analyse
all the observed outcome data via the maximum likeli-
hood method under the data missing at random (MAR)
assumption, which requires the inclusion of any relevant
predictors of missing data in the analysis model.
The current study therefore addressed these meth-
odological weaknesses by using a larger sample rando-
mized to either CBT/MED or TAU/MED and including
a 3-month follow-up. We performed an intention-to
treat analysis using a linear mixed model and analysed
for three possible predictors of missing data: gender,
age, and ASP traits. Thus we analysed the effects of
treatment over time (i.e. end of treatment versus at
3-month follow-up) as well as overall group differ-
ences in the outcome measures whilst controlling for
possible group imbalances caused by missing data. It
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was hypothesized that the CBT/MED group would
show signiﬁcantly greater reduction in the primary
outcomes of ADHD core symptoms and illness sever-
ity compared with the TAU/MED group after adjusting
for missing data and possible confounders. A similar
treatment effect was expected for secondary outcomes
of anxiety, depression and quality of life. Treatment
gains were expected to be maintained at 3-month
follow-up.
Method
Trial design
A parallel-group RCT was conducted at an ADHD out-
patient setting within the Mental Health Services at
Landspitali – The National University Hospital of
Iceland. All participants meeting inclusion criteria
were independently and individually randomly allo-
cated (1:1) to receive the R&R2ADHD programme
(CBT/MED) or treatment as usual (TAU/MED).
Assessments occurred at three time points: baseline,
end of treatment and 3 months after treatment. The
study was registered with the International Clinical
Trials Registry (no. 12611000533998).
An a priori power calculation was conducted using
G*Power (Faul et al. 2007) to estimate the sample size
required. Safren et al. (2005) obtained a large effect
size between CBT-treated medicated adults with
ADHD and those treated by medication only. In
view of the fact that the Safren et al. study involved in-
dividual rather than group therapy, where the effect
size is likely to be larger, we used an estimated effect
size of 0.50. The power was set at 80% and the level of
signiﬁcance at 0.05. This suggested a sample of n = 51 in
each group.
Participants
Participants were either hospital referrals for out-
patient rehabilitation made by the Mental Health
Services at the Landspitali University Hospital, refer-
rals from private practitioners or self-referrals from
an advertisement placed with a national ADHD sup-
port group (Icelandic ADHD Association). Participants
were eligible for the study if they were over 18 years of
age, had a current ADHD diagnosis and had been
stable on prescribed ADHD medication for at least
1 month. Participants were asked to keep dosages un-
changed during the study. Exclusion criteria were se-
vere mental illness (i.e. psychotic disorders, bipolar
disorder), severe eating disorder, active suicidal idea-
tion, active drug abuse and history of intellectual im-
pairment as the treatment programme would not be
suitable for these patient groups without modiﬁcation.
Exclusion criteria were assessed from a review of
medical records, in addition to a baseline assessment
by an experienced mental health practitioner (see
Baseline assessments section).
Of 187 referrals, 73 (39%) were received from private
practice psychiatrists, 56 (30%) were referred by psychia-
trists, psychologist or psychiatric nurses at the Mental
Health Services at Landspitali University Hospital and
56 (30%) were referred from advertisements to the mem-
bers of the Icelandic ADHD Association. Out of the 187
referrals, 95 (51%) participants took part in the study.
Fig. 1 presents the reasons for non-participation, the
most common being declining to participate (n = 30),
not contactable (n = 18) and stopped medication (n = 16).
Of the participants, 11 were excluded because at the
study intake interview (conducted by an experienced
mental health practitioner) they were not diagnosed
with ADHD [according to Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV criteria]; 62
of the participants were female (mean age = 35.00,
S.D. = 11.81 years) and 33 were male (mean age =
35.45, S.D. = 11.62 years).
Demographic and clinical characteristics of the study
sample are presented in Table 1. All medication was pre-
scribed by psychiatrists and, at baseline, 79 (83.2%) were
taking methylphenidate and 16 (16.8%) atomoxetine.
Five participants were also taking bupropion. In add-
ition,63 (66.3%)participantswere takingotherprescribed
medications (mean number of medications 2.45, S.D. =
1.39) includingantidepressants, benzodiazepines, insulin
and ibuprofen. Therewas considerable co-morbidity pre-
sent as, in addition to ADHD, participants reported co-
morbid depression (63.2%), anxiety (36.8%), and history
of drug/alcohol abuse (15.8%). Of the participants,
seven (7.4%) reported to have beendiagnosedwith a per-
sonality disorder and four with Asperger’s syndrome in
childhood. Four reported having post-traumatic stress
disorder and two with a history of eating disorder.
Interventions
R&R2ADHD is a CBT intervention programme devel-
oped for youth and adults with ADHD (Young &
Ross, 2007). It is a revised version of the 35-session
Reasoning & Rehabilitation prosocial competence
training programme which has a strong evidence
base (Tong & Farrington, 2006). It was revised to be
a shorter and more relevant intervention for indivi-
duals presenting with symptoms associated with
ADHD. The revision, R&R2ADHD, is a structured,
manualized programme consisting of 15 sessions of
90 min (excluding a mid-session break) and aims to de-
crease ADHD symptoms and improve social,
problem-solving and organizational skills. It has ﬁve
treatment modules: (a) neurocognitive, e.g. learning
strategies to improve attentional control, memory,
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impulse control and planning; (b) problem solving, e.g.
developing skilled thinking, problem identiﬁcation,
consequential thinking, managing conﬂict and making
choices; (c) emotional control, e.g. managing feelings of
anger and anxiety; (d) prosocial skills, e.g. recognition
of the thoughts and feelings of others, empathy, nego-
tiation skills, and conﬂict resolution; and (e) critical
reasoning, e.g. evaluating options and effective
behavioural skills. R&R2ADHD is a group treatment
supplemented by one-to-one meetings with a mentor.
In the present study the group sessions were delivered
twice per week. The mentors met with the participants
between each group session in order to support parti-
cipants to transfer skills learned in the group into their
daily lives. Programme integrity was ensured by group
sessions being delivered according to the manual by
Fig. 1. Flowchart of patient participation. ADHD, Attention-deﬁcit/hyperactivity disorder; CBT/MED, cognitive–behavioural
therapy plus medication; TAU/MED, treatment as usual plus medication.
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experienced CBT therapists, who had received training
and accreditation to deliver the programme. Thementor-
ing sessions were provided by psychology students who
also received training, supervision andwritten guidance.
Treatment completion was classiﬁed as ≥12 sessions,
representing 80% attendance of the programme.
TAU was classiﬁed as receiving usual treatment,
which included both pharmacological and non-
pharmacological treatments.
Measures
Baseline assessments
All referrals who could be contacted and who consented
to participate in the study were interviewed prior to
randomization to ascertain clinical diagnosis according
to DSM-IV criteria using the MINI International
Neuropsychiatric Interview (Sheehan et al. 1998) by an
experienced mental health practitioner. In addition, the
54-item Gough Socialization Scale (Gough, 1960) was
used to measure ASP traits because these have been
found to be associated with failure to attend follow-up
appointments after treatment in an Icelandic sample
(Gudjonsson et al. 2004). In addition, Young &
Gudjonsson (2006) found that community patients
diagnosed with ADHD commonly had ASP traits as
measured by the Gough Socialization Scale, which
might be related to missing follow-up data (dropouts).
There may of course be other possible confounding
variables not included in the analysis, such as sub-
stance misuse, which may act similarly to APD traits.
Sociodemographic data and medical information
from a review of clinical records were obtained (see
Table 1). In addition, a battery of psychometric tests
assessed the primary (ADHD core symptoms and ill-
ness severity) and secondary outcomes (anxiety, de-
pression, quality of life) at baseline, at the end of
treatment and at 3-month follow-up as follows.
Primary outcomes
The Kiddie-Schedule for Affective Disorders and
Schizophrenia (K-SADS), ADHD section, is a measure
Table 1. Demographic, clinical and baseline characteristics of the study sample (n = 95)
Total
(n = 95)
CBT/MED
(n = 48)
TAU/MED
(n = 47) Statistics
Gender, n (%)
Men 33 (43.7) 18 (37.5) 15 (31.9) χ2 = 0.327, p = 0.57
Women 62 (65.3) 30 (62.5) 32 (68.1)
Age, years
Mean 35.17 34.19 36.17 t93 = 0.826, p = 0.41
S.D. 11.68 10.58 12.75
Range 18–73 18–68 18–73
Marital status, n (%)
Single 47 (49.5) 23 (48.9) 24 (51.1) χ2 = 0.189, p = 0.66
In a relationship 47 (49.5) 24 (51.1) 23 (48.9)
Employment status, n (%)
Employed 41 (43.2) 18 (37.5) 23 (48.9) χ2 = 2.236, p = 0.33
Training 22 (23.2) 14 (29.2) 8 (17.0)
Pension/unemployed 32 (33.7) 16 (33.3) 16 (34.0)
Medical history, n (%)
History of serious illness 27 (28.4) 13 (27.1) 14 (29.8) χ2 = 0.085, p = 0.77
History of head trauma 36 (37.9) 19 (39.6) 17 (36.2) χ2 = 0.118, p = 0.73
History of serious accidents 33 (34.7) 17 (35.4) 16 (34.0) χ2 = 0.020, p = 0.89
History of receiving psychotherapy 69 (72.6) 33 (68.8) 36 (76.6) χ2 = 0.735, p = 0.39
ADHD-speciﬁc medication, n (%)
Methylphenidate 73 (83.2) 40 (83.3) 33 (83.0) χ2 = 0.002, p = 0.963
Atomoxetine 16 (16.8) 8 (16.7) 8 (17.0) χ2 = 0.002, p = 0.963
Bupropion 5 (5.3) 3 (6.3) 2 (4.3) χ2 = 0.234, p = 0.629
Other medicationsa 63 (66.3) 32 (66.7) 31 (66.0) χ2 = 0.005, p = 0.942
CBT/MED, Cognitive–behavioural therapy plus medication; TAU/MED, treatment as usual plus medication; S.D., standard
deviation; ADHD, attention-deﬁcit/hyperactivity disorder.
a Other medications include, for example, antidepressants, benzodiazepines, insulin, ibuprofen and various other
medications.
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of symptom change and severity of ADHD symptom-
atology (Kaufman et al. 1996). The 18-item question-
naire was completed by clinicians who were blind to
treatment allocation. Magnússon et al. (2006) have
reported that the scale has good reliability and validity
in an Icelandic sample.
TheClinicalGlobal Impression (CGI;National Institute
of Mental Health, 1985) is a single-question observer rat-
ing of severity of illness on a seven-point scale. It is based
on judgment regarding impairment in functioning,
symptom severity and distress or coping and is sup-
ported by examples of these factors. It was completed
by clinicians who were blind to treatment condition.
The CGI has been widely used in treatment evaluation
studies and has been found to correlate with ADHD se-
verity measured by the adult ADHD Investigator
Symptom Rating Scale (Spencer et al. 2010).
The Barkley Current Symptoms Scale (Barkley, 1998)
is an 18-item self-report questionnaire that measures
ADHD symptoms and corresponds with the DSM-IV
criteria (APA, 1994). The questionnaire consists of a
total scale made up from two subscales; one measures
inattention and the other hyperactivity/impulsivity.
Magnússon et al. (2006) found a high correlation be-
tween informants’ ratings of symptoms and interview-
based diagnoses in childhood and adulthood in an
Icelandic sample. The correlations were 0.49 (males)
and 0.58 (females) for childhood symptoms and 0.50
(males) and 0.55 (females) for symptoms in adulthood.
Secondary outcomes
The Beck Anxiety Inventory (BAI; Beck & Steer, 1993)
is a 21-item self-report questionnaire that is widely
used in clinical practice and research.
The Beck Depression Inventory (BDI; Beck et al.
1961) is a 21-item self-report questionnaire to assess
symptoms and severity of depression.
The Quality of Life Scale (QOLS; Flanagan, 1978,
1982) is a 16-item scale that assesses attitudes toward
a person’s own quality of life. The QOLS was original-
ly developed for research in healthy populations, but it
has been used in several international studies with
chronic illnesses (Burckhardt & Anderson, 2003) and
among cancer patients in Iceland (Friðriksdóttir et al.
2011). Burckhardt & Anderson (2003) have demon-
strated good construct validity of the scale in a sample
of chronically ill and healthy adults from American
and Swedish databases.
Procedure
All referrals who could be contacted and who agreed to
participate in the study were assessed for eligibility by
participating in an interview to conﬁrm their ADHD
diagnosis, andassess co-morbidity.Abatteryof self-rated
and clinician-rated evaluations (the latter being blind to
treatment allocation) was conducted at the three time
points (baseline, post-treatment and at 3-month follow-
up). Participants were randomized to either the CBT/
MED or TAU/MED condition. Randomization was con-
ducted independently by a psychiatrist at Landspitali
University Hospital, who was not involved in the
study. The psychiatrist had no information about the
participants and received numbers that were pre-
assigned to the participants. Block randomization by
using equal block sizes was performed at the time of
each study phase. Only the ﬁnal randomization numbers
were reported back to the researchers to protect the
concealment of the allocation as proposed in various
studies (Beller et al. 2002; Schulz & Grimes, 2002). The
R&R2ADHD programme was delivered twice per week
by experienced CBT therapists who had attended train-
ing to deliver the programme. Group participants met
their mentor between group sessions for at least 30 min.
Mentors attended a training session to fulﬁl this role
involving an introduction to the programme and the
mentoring role. In addition, mentors have a manual
that guides them through topics to be discussed within
the mentoring session. They received supervision once
a fortnight from the lead group therapist. There were
ﬁve R&R2ADHD treatment groups in total. Participants
in the TAU/MED condition received pharmacological
intervention and other non-pharmacological interven-
tions but these were not systematically provided or
recorded.
Statistical analyses
The statistical analysis involved two sequential steps.
First, we applied a logistic regression model to identify
factors (i.e. gender, age and ASP traits) that might pre-
dict the probability of missing data. Only age was
found to be signiﬁcantly associated with the probabil-
ity of dropouts (i.e. younger participants in both
groups more often failed to attend the assessment
interviews with the independent raters: K-SADS,
Z =−2.19, p = 0.029; CGI, Z =−2.35, p = 0.019).
Second, an intention-to-treat analysis (individuals
analysed in the group to which they were randomized)
of available outcome data was performed to estimate
the effect of offering the treatment using a linear
mixed model. In view of the signiﬁcant relationship
found between age and missing data dropouts, we
controlled for age in the linear mixed model. The ran-
dom component of the mixed model included a ran-
dom intercept term for subject identiﬁer to take
account of between-subject variability and the correl-
ation between the repeated measures. Within the
ﬁxed part of the model, the treatment effect was
adjusted for time (a binary indicator of whether an
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outcome measure corresponds to follow-up or end of
treatment) and the baseline measures of the respective
outcome inallmodels.We testedcondition × time interac-
tions, but none was found statistically signiﬁcant and
therefore these were excluded from the model.
The amount of missing data at baseline was min-
imal, but there was a substantial proportion (leading
up to 50% by the follow-up) of missing data in the
completion of the outcome measures due to study
dropouts. The dropout rate was similar for both the
CBT/MED and TAU/MED groups (see Fig. 1), with χ2
tests revealing no differences between groups.
Two of the commonly recommended approaches for
dealing with the risk of potential bias due to missing
data are multiple imputation and complete case ana-
lysis via maximum likelihood. Multiple imputation is
appropriate when there are missing data in covariates
which is not the case in our study. When missing data
occur only in the outcome variables then complete case
analysis via maximum likelihood produces unbiased
results, provided that the variables associated with
the outcome being missing are included as covariates
(under a MAR assumption). We adopted the complete
case analysis approach under a MAR assumption as
we had missing data only in the outcome variables.
Covariates driving missingness were identiﬁed using
a logistic regression analysis and an analysis of all
observed outcome data was performed using a linear
mixed model via maximum likelihood method control-
ling for predictors of missing data, which should pro-
duce unbiased estimates under a MAR assumption
(White et al. 2011).
Adjusted effect sizes (Cohen’s d) were obtained by
calculating the residuals from the respective linear
mixed model with the condition term excluded, and
then calculating the standardized mean difference of
the adjusted outcome (residuals) between groups.
The calculation was conducted using the user contrib-
uted STATA module COHEND (http://ideas.repec.org/
c/boc/bocode/s457235.html), which calculates effect sizes
by adjusting for uneven group sizes.
Descriptive characteristics of the demographic and
clinical sample data as well as the outcome measures
are presented as means and standard deviations. To as-
sess differences between the CBT/MED and TAU/MED
conditions at baseline, independent-sample t tests were
performed and χ2 tests were used to analyse categories
and categorical data, respectively.
Ethical standards
All procedures contributing to this work comply with
the ethical standards of the relevant national and institu-
tional committees on human experimentation and with
the Helsinki Declaration of 1975, as revised in 2008.
Results
Baseline characteristics
There were no signiﬁcant differences between the CBT/
MED and the TAU/MED groups in the demographic
background data (see Table 1). As far as the baseline
outcome measures are concerned, there were no sign-
iﬁcant differences between groups with the exception
that the TAU group had a lower Barkley Current
Symptoms Scale hyperactivity/impulsivity score com-
pared with the CBT group (Table 2).
Programme completion
Just over half of the participants completed the pro-
gramme (n = 25; 52.1%).
Outcomes
In Table 3 a selected output from the linear mixed
model analyses is given. Each row shows the coefﬁ-
cient of the treatment indicator (0 = TAU/MED, 1 =
CBT/MED) and the relevant inferential statistics of
the named outcome. All models included a random
intercept term for subject identiﬁcation and controlled
for age, time (indicator of whether the measurement
corresponds to end of treatment or follow-up or end
of treatment) and the baseline measurement differ-
ences of each respective outcome variable. Estimates
of the adjusted overall mean differences (i.e. combining
the scores from end of treatment and at 3-month
follow-up) between the CBT/MED and TAU/MED
groups and the corresponding p values are provided.
There was a signiﬁcant main effect for all the outcome
measures except for the BAI and quality of life mea-
sures. The group difference on the BAI was very
close to being statistically signiﬁcant at the 5% level,
which suggests that the CBT group tended to have a
considerably reduced BAI scores compared with the
TAU group.
Therewas anoverall effectof time (endof treatmentver-
sus 3-month follow-up) adjusted for baseline, group and
age, on the three secondary measures: BAI (Z =−2.53,
p = 0.011, d = 0.58), BDI (Z =−2.2, p = 0.025, d = 0.52) and
quality of life (Z = 2.47, p = 0.014, d = 0.56), showing steady
improvement over time in the treatment group. No sign-
iﬁcant time change was noted regarding the primary
outcome measures.
Discussion
Thiswas a randomized controlled (intention-to-treat ana-
lysis) study of the effectiveness of CBT (R&R2ADHD)
in medication-treated adults with ADHD. The study
employed a sophisticated analysis (using a linear mixed
model) to control for confounders associated with
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Table 2. Outcome measures in the CBT/MED and TAU/MED conditions and statistics of the baseline measurements
Outcome
CBT/MED TAU/MED Statistics of the baseline
measurements between
groupsBaseline End of treatment Follow-up Baseline End of treatment Follow-up
K-SADS total 39.96 (5.71) 30.60 (7.33) 30.95 (5.53) 37.53 (8.05) 35.47 (6.40) 35.67 (5.86) t79 = 1.253, p = 0.214
n 47 33 21 45 34 27
K-SADS inattention 21.70 (3.54) 16.55 (3.98) 17.43 (3.60) 20.87 (4.05) 19.88 (3.94) 19.26 (3.49) t90 = 1.054, p = 0.296
n 47 33 21 45 34 27
K-SADS hyperactivity/impulsivity 17.66 (3.76) 14.06 (4.45) 13.52 (3.86) 16.67 (4.78) 15.58 (4.15) 16.41 (3.93) t90 = 1.110; p = 0.270
n 47 33 21 45 34 27
CGI 3.96 (0.81) 3.03 (1.05) 3.14 (0.79) 3.91 (1.10) 3.79 (0.77) 3.80 (0.96) t90 = 0.231, p = 0.818
n 47 33 21 45 34 27
BCS combined 28.80 (9.26) 17.26 (7.58) 14.72 (8.31) 25.15 (11.09) 21.57 (9.75) 22.34 (9.17) t90 = 1.714, p = 0.090
n 46 34 25 46 35 32
BCS inattention 16.28 (5.49) 10.59 (4.40) 9.60 (5.34) 15.58 (6.57) 13.71 (5.72) 14.19 (5.85) t90 = 0.637, p = 0.526
n 46 34 25 46 35 32
BCS hyperactivity/impulsivity 12.52 (5.16) 6.68 (5.01) 5.12 (4.05) 9.63 (5.97) 7.86 (5.92) 8.16 (5.13) t90 = 2.448, p = 0.016
n 46 34 25 46 35 32
BAI anxiety 13.84 (8.69) 10.41 (9.10) 6.29 (4.53) 14.60 (7.43) 14.37 (10.67) 12.13 (7.65) t87 =−0.443, p = 0.659
n 44 34 24 45 35 31
BDI depression 12.72 (8.62) 8.38 (6.99) 5.04 (5.60) 16.09 (10.23) 14.00 (10.45) 13.14 (7.99) t87 =−1.690, p = 0.095
n 46 34 24 43 34 29
Quality of life 71.38 (14.40) 74.50 (14.53) 79.84 (11.07) 69.54 (14.91) 70.94 (16.29) 72.22 (14.31) t89 = 0.595, p = 0.553
n 45 34 25 46 35 32
Data are given as mean (standard deviation).
CBT/MED, Cognitive–behavioural therapy plus medication; TAU/MED, treatment as usual plus medication; K-SADS, Kiddie-Schedule for Affective Disorders and Schizophrenia,
attention-deﬁcit/hyperactivity disorder section; CGI, Clinical Global Impression; BCS, Barkley Current Symptoms Scale; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory.
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missing data, between-subject variability, and the cor-
relation between the measures over time. The current
study thus provides a more rigorous methodology
and robust statistical analysis of outcome than used
in previous research. In the current study, the treat-
ment effect in the model was adjusted for time,
which allowed us to investigate whether or not the
treatment effectiveness noted at the end of treatment
was maintained or improved at 3 months follow-up,
in addition to investigating the overall effect of the
end of treatment and 3-month follow-up combined.
The results revealed several robust ﬁndings. As
hypothesized, the CBT/MED group showed overall
(combined outcome at post-treatment and follow-up)
signiﬁcantly greater reduction in all the primary out-
comes of ADHD core symptoms and illness severity
compared with TAU/MED group with a medium effect
size for the independent raters on the K-SADS total
and CGI and slightly less marked ﬁndings for the self-
reported ADHD symptoms. A signiﬁcant overall treat-
ment effect was found for the secondary outcome of
self-reported depression (small effect size) but, con-
trary to our hypothesis, this was not quite signiﬁcant
for anxiety and quality of life. As hypothesized, the
treatment effect of primary outcomes was maintained
at the 3-month follow-up.
Importantly, in contrast to the primary outcome
measures, the three secondary measures (anxiety,
depression and quality of life) showed a signiﬁcant
improvement over time, all with a medium effect
size. This has not been investigated before. One inter-
pretation is that the effect of the CBT treatment is
more immediate with regard to the ADHD symptoms
and illness severity, whereas symptoms of anxiety and
depression and rating of quality of life improve more
gradually over time, and may indeed continue to im-
prove. The Emilsson et al. (2011) study did not include
a measure of quality of life and the current study is the
ﬁrst study in this area to include one at follow-up. An
alternative explanation is that the secondary measures
effects are programme speciﬁc as the R&R2ADHD
aims to reduce co-morbidity as well as primary symp-
toms. However, when comparing results from the pre-
sent study with those reported by Emilsson et al.
(2011), the effect sizes are generally smaller. This
most probably reﬂects the use of a more sophisticated
analysis that better controlled for confounders and
thus provided more robust ﬁndings. A follow-upof sec-
ondary measures should be included in future studies,
perhapsusing a longer-term follow-up. Theﬁndings sug-
gest that focusing exclusively on ADHD measures and
symptom severity, like Safren et al. (2010), limits the con-
clusions that can be drawn about other health beneﬁts
and improved quality of life. This is particularly import-
ant in studies that include participants with a high base
level of co-morbid problems. Hirvikoski et al. (2011) and
Solanto et al. (2010) did collect data on co-morbid pro-
blems but they only included end-of-treatment data,
which showed non-signiﬁcant results. Ideally, treatment
effectiveness should improve over time, or at least be
maintained, as participants continue to practise the skills
learnedduring therapyandgradually improve their level
of competencies and day-to-day functioning. Further
studies need to investigate the mechanisms that facilitate
the maintenance and/or changes in outcome over time.
Just over half of the sample completed the group
treatment. This is considerably lower than completion
rates reported by forensic in-patient samples attending
Table 3. Estimated treatment effect from the linear mixed-model analyses with adjusted effect sizes (Cohen’s d) from the model
Outcome β Coefﬁcient S.E. p 95% CI Effect size: d
K-SADS total −5.41 1.03 <0.001 −7.43 to −3.38 0.65
K-SADS inattention −3.22 0.70 <0.001 −4.6 to −1.84 0.56
K-SADS −2.11 0.60 <0.001 −3.29 to −0.93 0.51
hyperactivity/impulsivity
CGI −0.79 0.17 <0.001 −1.12 to −0.46 0.64
BCS combined −6.60 1.33 <0.001 −9.19 to −3.99 0.46
BCS inattention −3.63 0.80 <0.001 −5.21 to −2.06 0.42
BCS −3.10 0.73 <0.001 −4.50 to −1.63 0.46
hyperactivity/impulsivity
BAI anxiety −3.11 1.72 0.071 −6.49 to 0.26 0.21
BDI depression −4.84 1.51 0.001 −7.79 to −1.89 0.32
Quality of life 3.36 2.50 0.180 −1.55 to 8.26 0.14
S.E., Standard error; CI, conﬁdence interval; K-SADS, Kiddie-Schedule for Affective Disorders and Schizophrenia, attention-
deﬁcit/hyperactivity disorder section; CGI, Clinical Global Impression; BCS, Barkley Current Symptoms Scale; BAI, Beck
Anxiety Inventory; BDI, Beck Depression Inventory.
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R&R2 (Rees-Jones et al. 2012; Cin-Ying Yip et al. 2013;
Young et al. 2013; Waugh et al. 2014; Jotangia et al.
2015). However, the attrition rate of patients attending
community-led treatments has been reported to be
high (e.g. Issakidis & Andrews, 2004). Nevertheless,
whilst the present study’s completion rate is not
particularly poor in comparison with other similar
community studies, it means that many of the partici-
pants missed several of the sessions. In turn this may
have adversely inﬂuenced the treatment effect, as par-
ticipants who drop out are unlikely to reach optimal
beneﬁt from treatment. Ways for improving treatment
completion in community samples need to be consid-
ered a priority in future studies.
A large number of participants (in both the CBT/
MED and TAU/MED groups) did not attend the ses-
sions to complete their post-treatment assessments. A
similar problem with missing data dropout was
noted by Emilsson et al. (2011) and this was higher
than that reported by Safren et al. (2010), Solanto
et al. (2010) and Hirvikoski et al. (2011). It is not clear
whether this is due to the nature of the participants,
the severity of their symptoms, practical considerations
such as the Icelandic climate (poor weather and travel
conditions), or a reﬂection of the broader Icelandic
community. For example, only 27% of patients
attended their follow-up appointment in a large com-
munity study evaluating a substance misuse treatment
in Reykjavik despite reminders by letter and a subse-
quent telephone call (Gudjonsson et al. 2004). Those
patients who failed to attend their follow-up appoint-
ment were signiﬁcantly younger than those who
attended, were more antisocial in their personality,
and had a higher level of trait anxiety. The current
ﬁndings conﬁrm the negative relationship between
age and attendance at follow-up appointments, but
not for ASP traits. Future studies should consider in-
corporating predictors of missing data into the linear
mixed-model analysis in the event of group differ-
ences. This is particularly important when comparing
participants who drop out of treatment versus those
who complete all sessions (Everitt & Pickles, 1999).
Strengths of the study were the use of independent
raters who were blind to treatment condition and the
consistency of these scores with those obtained from
the participants’ self-report. This suggests that the par-
ticipants were not amplifying the beneﬁts of treatment.
The study’s main limitation is the high dropout rate,
which left us with a substantially reduced sample at
follow-up. Second, in total there were 10 individual
outcome measures (see Table 3), which increase the
chance of a type I error although eight out of the 10
variables were signiﬁcant at ≤0.001, which reduces
the likelihood this has occurred. However, the TAU/
MED group did not receive any additional control
intervention, which may have inﬂated the treatment
effects in the CBT/MED group.
The study adds substantially to knowledge by pro-
viding convincing evidence for the effectiveness of
R&R2ADHD and demonstrates that there are likely
to be differential effects over time (end of treatment
versus follow-up) with regard to primary ADHD out-
comes versus co-morbid problems. Co-morbid pro-
blems are likely to take longer to show positive effect
than the core ADHD symptoms. A possible explan-
ation is that the disruptive behaviour commonly aris-
ing from ADHD symptoms increases the risk of
depression due to the negative reactions of others to
their behaviour (Roy, 2014). R&R2ADHD treatment
improves ADHD symptoms and disruptive behaviour,
which over time are likely to reduce co-morbid symp-
toms due to a more positive reaction from peers,
friends and family members. The current time differ-
ence found in treatment effects between core ADHD
symptoms and co-morbid problems is likely to be
related to the different developmental pathways of
these conditions.
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